elranatamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
rat origin 5741 2408850-14-4

Description:

MoleculeDescription

Molfile

Synonyms:

  • elranatamab
  • elranatamab-bcmm
  • PF-06863135
  • RN613
  • elrexfio
Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 14, 2023 FDA PFIZER INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 699.21 49.55 143 1215 27830 90599259
Cytomegalovirus infection reactivation 176.65 49.55 37 1321 7763 90619326
Immune effector cell-associated neurotoxicity syndrome 163.67 49.55 33 1325 5735 90621354
Cytomegalovirus infection 96.03 49.55 29 1329 26573 90600516
Malignant neoplasm progression 59.81 49.55 30 1328 106840 90520249
Neutropenia 55.44 49.55 37 1321 224867 90402222
Hypogammaglobulinaemia 53.36 49.55 15 1343 10659 90616430

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 518.06 33.75 145 1376 44382 42575432
Immune effector cell-associated neurotoxicity syndrome 161.50 33.75 42 1479 9419 42610395
Cytomegalovirus infection reactivation 95.97 33.75 29 1492 11149 42608665
Cytomegalovirus infection 72.49 33.75 31 1490 32275 42587539
Malignant neoplasm progression 57.74 33.75 40 1481 108360 42511454
Hypogammaglobulinaemia 53.77 33.75 19 1502 11872 42607942
Infection 47.45 33.75 36 1485 112032 42507782
Neoplasm progression 43.38 33.75 21 1500 28979 42590835
Pyrexia 43.31 33.75 61 1460 393981 42225833
Second primary malignancy 42.14 33.75 15 1506 9560 42610254
COVID-19 39.93 33.75 33 1488 115915 42503899

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 1062.19 38.85 265 2672 70041 110516321
Immune effector cell-associated neurotoxicity syndrome 309.76 38.85 73 2864 14709 110571653
Cytomegalovirus infection reactivation 259.24 38.85 66 2871 18267 110568095
Cytomegalovirus infection 158.11 38.85 58 2879 54386 110531976
Malignant neoplasm progression 114.56 38.85 66 2871 174501 110411861
Hypogammaglobulinaemia 112.19 38.85 35 2902 20041 110566321
Neoplasm progression 72.45 38.85 35 2902 64560 110521802
Pyrexia 61.01 38.85 95 2842 898170 109688192
Second primary malignancy 58.91 38.85 21 2916 18047 110568315
Cytomegalovirus viraemia 51.75 38.85 19 2918 17745 110568617
Pneumonia bacterial 51.27 38.85 21 2916 26240 110560122
Death 48.84 38.85 75 2862 698794 109887568
Neutropenia 47.62 38.85 54 2883 374566 110211796
COVID-19 43.04 38.85 42 2895 245018 110341344
Cytomegalovirus chorioretinitis 42.20 38.85 13 2924 7115 110579247

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX32 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamabipilimumab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsed or refractory multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen ANTIBODY BINDING Kd 10.42 DRUG LABEL DRUG LABEL
T-cell surface glycoprotein CD3 epsilon chain Surface antigen ANTIBODY BINDING Kd 7.77 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757254 CHEBI
CHEMBL4297809 ChEMBL_ID
C000731940 MESH_SUPPLEMENTAL_RECORD_UI
12889 IUPHAR_LIGAND_ID
DB15395 DRUGBANK_ID
2054141000122109 SNOMEDCT_US
4042513 VANDF
4042514 VANDF
C5667166 UMLSCUI
11838 INN_ID
370309 MMSL
41902 MMSL
d10095 MMSL
019524 NDDF
D12058 KEGG_DRUG
L0HR9A577V UNII
2644880 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Elrexfio HUMAN PRESCRIPTION DRUG LABEL 1 0069-2522 INJECTION, SOLUTION 44 mg SUBCUTANEOUS BLA 30 sections
Elrexfio HUMAN PRESCRIPTION DRUG LABEL 1 0069-4494 INJECTION, SOLUTION 76 mg SUBCUTANEOUS BLA 30 sections
Elrexfio HUMAN PRESCRIPTION DRUG LABEL 1 63539-252 INJECTION, SOLUTION 44 mg SUBCUTANEOUS BLA 30 sections